Anti-proliferative and cytoskeleton-disruptive effects of icariin on HepG2 cells

Molecular Medicine Reports

Volumn 12, Issue 5, 2015, Pages 6815-6820

  Wang, Zhi Min ^a   Song, Nan ^a   Ren, Yan Ling ^a  

^a LIAONING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Cytoskeleton; HepG2; Icariin; Proliferation

Indexed keywords

F ACTIN; ICARIIN; OXALIPLATIN; PROTEIN BCL 2; ACTIN; ANTINEOPLASTIC AGENT; BCL2 PROTEIN, HUMAN; FLAVONOID;

ACTIN POLYMERIZATION; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOSKELETON; DRUG EFFECT; FLUORESCENCE ACTIVATED CELL SORTING; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IC50; IMMUNOHISTOCHEMISTRY; MTT ASSAY; PROTEIN EXPRESSION; TREATMENT DURATION; WESTERN BLOTTING; DRUG EFFECTS; DRUG SCREENING; G1 PHASE CELL CYCLE CHECKPOINT; METABOLISM;

ACTINS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CYTOSKELETON; DRUG SCREENING ASSAYS, ANTITUMOR; FLAVONOIDS; G1 PHASE CELL CYCLE CHECKPOINTS; HEP G2 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84943611679     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4282     Document Type: Article

References (29)

1. Adams JM and Cory S: The Bcl-2 protein family: Arbiters of cell survival. Science 281: 1322-1326, 1998.
2. Bell RM: A review of complementary and alternative medicine practices among cancer survivors. Clin J Oncol Nurs 14: 365-370, 2010.
3. Chang HC, Chen TL and Chen RM: Cytoskeleton interruption in human hepatoma HepG2 cells induced by ketamine occurs possibly through suppression of calcium mobilization and mitochondrial function. Drug Metab Dispos 37: 24-31, 2009.
4. Colombo E, Marine J-C, Danovi D, Falini B and Pelicci PG: Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 4: 529-533, 2002.
5. Hall A: Rho GTPases and the actin cytoskeleton. Science 279: 509-514, 1998.
6. He W, Sun H, Yang B, Zhang D and Kabelitz D: Immunoregulatory effects of the herba Epimediia glycoside icariin. Arzneimittelforschung 45: 910-913, 1995.
7. Huo X, Xu XJ, Chen YW, Yang HW and Piao ZX: Filamentous-actins in human hepatocarcinoma cells with CLSM. World J Gastroenterol 10: 1666-1668, 2004.
8. Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD: The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science 275: 1132-1136, 1997.
9. Lau WY and Lai EC: Hepatocellular carcinoma: Current management and recent advances. Hepatobiliary Pancreat Dis Int 7: 237-257, 2008.
10. Liu WJ, Xin ZC, Xin H, Yuan YM, Tian L and Guo YL: Effects of icariin on erectile function and expression of nitric oxide synthase isoforms in castrated rats. Asian J Androl 7: 381-388, 2005.
11. Fiume L, Manerba M, Vettraino M and Di Stefano G: Effect of sorafenib on the energy metabolism of hepatocellular carcinoma cells. Eur J Pharmacol 670: 39-43, 2011.
12. Okuda K: Hepatocellular carcinoma: Recent progress. Hepatology 15: 948-963, 1992.
13. Shi MD, Liao YC, Shih YW and Tsai LY: Nobiletin attenuates metastasis via both ERK and PI3K/Akt pathways in HGF-treated liver cancer HepG2 cells. Phytomedicine 20: 743-752, 2013.
14. Shumilina EV, Negulyaev YA, Morachevskaya EA, Hinssen H and Khaitlina SY: Regulation of sodium channel activity by capping of actin filaments. Mol Biol Cell 14: 1709-1716, 2003.
15. Sun L, Chen W, Qu L, Wu J and Si J: Icaritin reverses multidrug resistance of HepG2/ADR human hepatoma cells via downregulation of MDR1 and P-glycoprotein expression. Mol Med Rep 8: 1883-1887, 2013.
16. Tong JS, Zhang QH, Huang X, et al: Icaritin causes sustained ERK1/2 activation and induces apoptosis in human endometrial cancer cells. PLoS One 6: e16781, 2011.
17. Zhang XH, Zou ZQ, Xu CW, Shen YZ and Li D: Myricetin induces G2/M phase arrest in HepG2 cells by inhibiting the activity of the cyclin B/Cdc2 complex. Mol Med Rep 4: 273-277, 2011.
18. Tan W, Lu J, Huang M, Li Y, Chen M, Wu G, Gong J, Zhong Z, Xu Z, Dang Y, et al: Anti-cancer natural products isolated from chinese medicinal herbs. Chin Med 6: 27, 2011.
19. Wang QQ, Zhang ZY, Xiao JY, Yi C, Li LZ, Huang Y and Yun JP: Knockdown of nucleophosmin induces S-phase arrest in HepG2 cells. Chin J Cancer 30: 853-860, 2011.
20. Wang Y, Dong H, Zhu M, Ou Y, Zhang J, Luo H, Luo R, Wu J, Mao M, Liu X, et al: Icariin exterts negative effects on human gastric cancer cell invasion and migration by vasodilator-stimulated phosphoprotein via Rac1 pathway. Eur J Pharmacol 635: 40-48, 2010.
21. Hu W and Kavanagh JJ: Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 4: 721-729, 2008.
22. Williams JI, Weitman S, Gonzalez CM, Jundt CH, Marty J, Stringer SD, Holroyd KJ, Mclane MP, Chen Q, Zasloff M and Von Hoff DD: Squalamine treatment of human tumors in nu/nu mice enhances platinum-based chemotherapies. Clin Cancer Res 7: 724-733, 2001.
23. Skillman KM, Diraviyam K, Khan A, et al: Evolutionarily divergent, unstable filamentous actin is essential for gliding motility in apicomplexan parasites. PLoS Pathog 7: e1002280, 2011.
24. Ozyamak E, Kollman JM and Komeili A: Bacterial actins and their diversity. Biochemistry 52: 6928-6939, 2015.
25. Xu HB and Huang ZQ: Icariin enhances endothelial nitric-oxide synthase expression on human endothelial cells in vitro. Vascul Pharmacol 47: 18-24, 2007.
26. Yan MX, Yang J, Sun Q, Liu CH, Wang YG and Wang WQ: Hepatocellular carcinoma that arose from primary Sjögren's syndrome. Ann Hepatol 12: 824-829, 2013.
27. Yang JX, Fichtner I, Becker M, Lemm M and Wang XM: Anti-proliferative efficacy of icariin on HepG2 hepatoma and its possible mechanism of action. Am J Chin Med 37: 1153-1165, 2009.
28. Yang YL: Polymerization of actins. Biology (Basel) 18: 13-14, 1995.
29. Zhang DW, Cheng Y, Wang NL, Zhang JC, Yang MS and Yao XS: Effects of total flavonoids and flavonol glycosides from Epimedium koreanum Nakai on the proliferation and differentiation of primary osteoblasts. Phytomedicine 15: 55-61, 2008.